

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
	10/605,840 10/30/2003		Itzhak Bentwich	06087.0300.CPUS11	2839	
	22930 75	590 04/24/2006		EXAMINER		
HOWREY LLP C/O IP DOCKETING DEPARTMENT 2941 FAIRVIEW PARK DR, SUITE 200 FALLS CHURCH, VA 22042-2924				BRUSCA,	BRUSCA, JOHN S	
	ART UNIT	PAPER NUMBER				
				1631		
				DATE MAILED: 04/24/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/605,840	BENTWICH, ITZHAK				
		Examiner	Art Unit				
		John S. Brusca	1631				
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with the c	orrespondence address				
WHIC - Exter after - If NO - Failu Any	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status	Status Status						
1)	Responsive to communication(s) filed on						
· —		 s action is non-final.					
3)□	Since this application is in condition for allower		secution as to the merits is				
·	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	Disposition of Claims						
4)🖂	Claim(s) <u>1-20</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
	5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected.						
6)							
7)	Claim(s) is/are objected to.						
8)🖾	8) Claim(s) 1-20 are subject to restriction and/or election requirement.						
Applicati	Application Papers						
9)[9)☐ The specification is objected to by the Examiner.						
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) 🔲 .	11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	nder 35 U.S.C. § 119						
_	12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
	1. Certified copies of the priority documen	ts have been received.					
	2. Certified copies of the priority document	ts have been received in Application	on No				
	3. Copies of the certified copies of the price		d in this National Stage				
	application from the International Burea	* **					
* S	* See the attached detailed Office action for a list of the certified copies not received.						
Attachment	(s)						
	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice 3) Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail Da	te atent Application (PTO-152)				
	No(s)/Mail Date	6) Other:	мен Аррисацон (СТО-132)				

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - 1. Claims 1-8, 12, and 14 drawn to a viral gene and vectors comprising the gene, classified in class 435, subclass 320.1.
 - 2. Claims 9 and 10, drawn to a method of inhibiting translation by use of a viral gene, classified in class 435, subclass 6.
 - 3. Claim 13, drawn to a method of using a probe, classified in class 435, subclass 6.
 - 4. Claims 15-20, drawn to an antiviral compound and method of use, classified in class 514, subclass 1.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions 1 and inventions 2 and 3 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the viral gene of Group 1 could be used in either of the methods of Groups 2 or 3.
- 3. Inventions 1 and 4 are directed to related products. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See

MPEP § 806.05(j). In the instant case, the viral gene of invention 1 encodes an RNA that is neutralized by the compound of Group 4. Because the structures and functions of the two products are different, the two products are distinct.

- 4. Inventions 2 and 3 are directed to related methods. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the methods of Groups 2 and 3 comprise different steps and produce different results, in Group 2 the result is inhibition of translation, while in Group 3 the result is hybridization to a nucleic acid probe.
- 5. Inventions 2 and 4 are directed to related products and methods. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the method of inhibiting translation of Group 2 does not use or product the antiviral compound of Group 4.
- 6. Inventions 3 and 4 are directed to related products and methods. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the method of using a probe of Group 3 does not use or product the antiviral compound of Group 4.

Application/Control Number: 10/605,840

Art Unit: 1631

7. Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Page 4

- 8. Because these inventions are independent or distinct for the reasons given above and the inventions of Groups 2 and 3 require a different field of search because they are drawn to methods with different steps that produce different results, (see MPEP § 808.02), restriction for examination purposes as indicated is proper.
- 9. For each of Groups 1-4, all claims are generic to the following disclosed patentably distinct species: A target of the encoded RNA. The species are independent or distinct because each target of the encoded RNA has a different sequence and a different biological function.

 Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of target of the encoded RNA, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/605,840

Art Unit: 1631

10. Sequence Election Requirement Applicable to All Groups

In addition, each Group detailed above reads on patentably distinct sequences. Each sequence is patentably distinct because they are unrelated sequences, and a further restriction is applied to each Group. For the elected Group, the Applicants must elect one nucleic acid sequence that is a described SEQ ID NO or an otherwise described nucleotide sequence. Examination will be restricted to only the elected sequence.

11. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Application/Control Number: 10/605,840

Art Unit: 1631

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Conclusion

12. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also

Art Unit: 1631

enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center at (800) 786-9199. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, PhD. can be reached on 571 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

John S. Brusca
Primary Examiner
Art Unit 1631

jsb